Back to results
US 2023/0181685 A1Published application
Antiviral compositions and methods
AssigneeWayne State University
InventorsGil MOR, Jiahui DING, Qianqian LI, Jianjun WANG
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeWayne State University
InventorsGil MOR, Jiahui DING, Qianqian LI, Jianjun WANG
Estimating the term…
Compositions and methods are provided according to aspects of the present disclosure for inhibition of a pathogenic virus. According to particular aspects, compositions and methods of the present disclosure include degradation of pathogenic viral nucleic acids by interferon-stimulated gene 20-kDa protein (ISG20) and/or a variant thereof, administered to a cell and/or subject to inhibit a pathogenic viral infection of the cell and/or a subject. Compositions and methods are provided according to aspects of the present disclosure wherein providing the ISG20 protein, or a variant thereof, comprises administering a therapeutically effective amount of the ISG20 protein and/or variant, to a subject having, or at risk of having, a viral infection.
A method of inhibiting a pathogenic virus, comprising:
The method of any of claims 1 to 12, wherein administering the ISG20 protein to a subject having, or at risk of having, a viral infection comprises administering a nucleic acid molecule encoding the ISG20 protein.
A method of inhibiting a Zika virus in a pregnant subject, comprising:
A composition, comprising a protein transduction reagent-modified ISG20 protein and a cell targeting component.
The composition of any of claims 29 to 34, wherein the cell targeting component comprises an Fc domain of human IgG1.
A method of inhibiting a pathogenic virus substantially as shown and/or described herein.
A composition comprising a protein transduction reagent-modified ISG20 protein and a cell targeting component substantially as shown and/or described herein.
A composition comprising a protein transduction reagent-modified ISG20 protein and a cell targeting component, wherein the cell targeting component is an Fc domain of human IgG1, the composition comprising a fusion protein substantially as shown and/or described herein.
Dependencies are inferred from the claim text.